Automated Triplex (HBV, HCV and HIV) NAT Assay Systems for Blood Screening in India

Overview

Journal J Clin Diagn Res

Specialty General Medicine

Date 2016 Apr 5

PMID 27042485

Citations 2

Authors

Manoj Kumar Rajput

Affiliations

Soon will be listed here.

Abstract

This review is confined to triplex nucleic acid testing (NAT) assays to be used on fully automated platform. Around the world, these assays are being used at various transfusion medicine centres or blood banks to screen blood units for HBV, HCV and HIV. These assay systems can screen up to 1000 blood units for HBV, HCV and HIV simultaneously in a day. This area has been dominated by mainly two manufacturers: M/s Gen-Probe-Novartis and M/s Roche Molecular Systems. The triplex NAT assay systems of both manufacturers are licensed by United States Food and Drug Administration. There is not much awareness about the technology and procedures used in these assays. The main objective of this review is to create awareness about the technology and procedure of these assays.

Citing Articles

Blood Donation Screening of Transfusion-Transmissible Viral Infection Using Two Different Nucleic Acid Testing (NAT) Platforms: A Single Tertiary Care Oncology Centre Experience.

Pathak A, Panda D, Sharma M, Tejwani N, Mehta A Indian J Hematol Blood Transfus. 2023; 39(3):456-463.

PMID: 37304490 PMC: 10247654. DOI: 10.1007/s12288-022-01598-y.

Self-testing for HIV, HBV, and HCV using finger-stick whole-blood multiplex immunochromatographic rapid test: A pilot feasibility study in sub-Saharan Africa.

Tonen-Wolyec S, Djangeinga R, Batina-Agasa S, Tshilumba C, Muwonga Masidi J, Hayette M PLoS One. 2021; 16(4):e0249701.

PMID: 33836036 PMC: 8034751. DOI: 10.1371/journal.pone.0249701.

References

Stramer S, Zou S, Notari E, Foster G, Krysztof D, Musavi F . Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value?. Transfusion. 2011; 52(2):440-6. DOI: 10.1111/j.1537-2995.2011.03283.x. View

Chudy M, Hanschmann K, Kress J, Nick S, Campos R, Wend U . First WHO International Reference Panel containing hepatitis B virus genotypes A-G for assays of the viral DNA. J Clin Virol. 2012; 55(4):303-9. DOI: 10.1016/j.jcv.2012.08.013. View

Chatterjee K, Coshic P, Borgohain M, Premchand , Thapliyal R, Chakroborty S . Individual donor nucleic acid testing for blood safety against HIV-1 and hepatitis B and C viruses in a tertiary care hospital. Natl Med J India. 2013; 25(4):207-9. View

Weusten J, Vermeulen M, van Drimmelen H, Lelie N . Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion. 2010; 51(1):203-15. DOI: 10.1111/j.1537-2995.2010.02804.x. View

Chudy M, Kress J, Halbauer J, Heiden M, Funk M, Nubling C . Risk Minimization Measures for Blood Screening HIV-1 Nucleic Acid Amplification Technique Assays in Germany. Transfus Med Hemother. 2014; 41(1):45-51. PMC: 3949608. DOI: 10.1159/000357103. View

Muller M, Fraile M, Hourfar M, Peris L, Sireis W, Rubin M . Evaluation of two, commercial, multi-dye, nucleic acid amplification technology tests, for HBV/HCV/HIV-1/HIV-2 and B19V/HAV, for screening blood and plasma for further manufacture. Vox Sang. 2012; 104(1):19-29. DOI: 10.1111/j.1423-0410.2012.01635.x. View

Maresch C, Schluter P, Wilson A, Sleigh A . Residual infectious disease risk in screened blood transfusion from a high-prevalence population: Santa Catarina, Brazil. Transfusion. 2007; 48(2):273-81. DOI: 10.1111/j.1537-2995.2007.01521.x. View

Vermeulen M, Coleman C, Mitchel J, Reddy R, van Drimmelen H, Ficket T . Sensitivity of individual-donation and minipool nucleic acid amplification test options in detecting window period and occult hepatitis B virus infections. Transfusion. 2013; 53(10 Pt 2):2459-66. PMC: 5061036. DOI: 10.1111/trf.12218. View

Margaritis A, Brown S, Seed C, Kiely P, dAgostino B, Keller A . Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA. Transfusion. 2007; 47(10):1783-93. DOI: 10.1111/j.1537-2995.2007.01343.x. View

10.

Pomper G, Wu Y, Snyder E . Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol. 2003; 10(6):412-8. DOI: 10.1097/00062752-200311000-00003. View

11.

Stramer S, Krysztof D, Brodsky J, Fickett T, Reynolds B, Phikulsod S . Sensitivity comparison of two Food and Drug Administration-licensed, triplex nucleic acid test automated assays for hepatitis B virus DNA detection and associated projections of United States yield. Transfusion. 2011; 51(9):2012-22. DOI: 10.1111/j.1537-2995.2011.03140.x. View

12.

Mathur A, Shah J, Shah R, Shah P, Harimoorthy V, Choudhury N . A study on optimization of plasma pool size for viral infectious markers in Indian blood donors using nucleic acid amplification testing. Asian J Transfus Sci. 2012; 6(1):50-2. PMC: 3353635. DOI: 10.4103/0973-6247.95056. View

13.

Bouchardeau F, Girault A, Razer A, Servant-Delmas A, Mercier M, Laperche S . Sensitivity of hepatitis B virus DNA transcription-mediated amplification testing in hepatitis B surface antigen-positive blood donations. Transfusion. 2006; 46(12):2047-52. DOI: 10.1111/j.1537-2995.2006.01031.x. View

14.

Louisirirotchanakul S, Oota S, Khuponsarb K, Chalermchan W, Phikulsod S, Chongkolwatana V . Occult hepatitis B virus infection in Thai blood donors. Transfusion. 2011; 51(7):1532-40. DOI: 10.1111/j.1537-2995.2010.03023.x. View

15.

Yaseen S, Ahmed S, Johan M, Kiron R, Daher A . Evaluation of serological transfusion-transmitted viral diseases and mutliplex nucleic acid testing in malaysian blood donors. Transfus Apher Sci. 2013; 49(3):647-51. DOI: 10.1016/j.transci.2013.07.003. View

16.

Albertoni G, Batista Castelo Girao M, Schor N . Mini review: current molecular methods for the detection and quantification of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. Int J Infect Dis. 2014; 25:145-9. DOI: 10.1016/j.ijid.2014.04.007. View

17.

Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P, Guitton C . Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201. Transfusion. 2008; 49(2):289-300. DOI: 10.1111/j.1537-2995.2008.01965.x. View

18.

Hourfar M, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch M . Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion. 2008; 48(8):1558-66. DOI: 10.1111/j.1537-2995.2008.01718.x. View

19.

Phikulsod S, Oota S, Tirawatnapong T, Sakuldamrongpanich T, Chalermchan W, Louisirirotchanakul S . One-year experience of nucleic acid technology testing for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations. Transfusion. 2009; 49(6):1126-35. DOI: 10.1111/j.1537-2995.2009.02176.x. View

20.

Roth W, Busch M, Schuller A, Ismay S, Cheng A, Seed C . International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang. 2011; 102(1):82-90. DOI: 10.1111/j.1423-0410.2011.01506.x. View